Amylin D rops on Byetta Supply Crunnch
NEW YORK (AP) - Amylin Pharmaceuticals Inc. shares dipped Thursday after
the biotech company fell short of Wall Street expectations and said that
demand for its Byetta treatment has exceeded supply. <snip>
I’m glad I have more than one month onboard in the fridge! <s>